LUNG CANCER: PRECISION MEDICINE'S GREATEST VICTORY
Lung cancer continues to represent one of the most challenging battles in modern oncology, claiming more lives globally than any other form of cancer. However, the medical landscape is experiencing a revolutionary transformation through precision medicine approaches. The revolutionary regulatory clearance of telisotuzumab vedotin (Emrelis) by the FDA in May 2025 demonstrates this transformative approach to cancer care, providing precision therapy for individuals whose tumors exhibit elevated c-Met protein levels and delivering remarkable 35% therapeutic response rates among patients who had received prior treatments. This cutting-edge therapeutic intervention is specifically designed to combat non-small-cell lung cancer (NSCLC), a cancer subtype that accounts for roughly 85% of all lung cancer cases worldwide. As we explore this comprehensive overview, we'll examine how precision medicine is reshaping treatment strategies and providing renewed hope for patients and their families ...